Blue Cross Denied Tracy Pike’s Cancer Surgery the Night Before. One Doctor Who Said No Was an OB-GYN.

The night before Tracy Pike was supposed to start the cancer treatment his surgeon believed could save his life, the surgeon called with bad news: his insurer would not pay. Blue Cross and Blue Shield of Illinois had labeled the roughly $40,000 procedure “not medically necessary” because it was “experimental, investigational and unproven.” Pike died in January 2024.

His story, first reported by Gretchen Morgenson of NBC News’ investigations unit in December 2024, is worth revisiting. It is a case study in what happens when the people collecting the premiums get the last word over the doctor.

A father, a diagnosis, a plan

Pike was 45, a father of three and the maintenance chief of a Louisville, Kentucky, skyscraper when he was diagnosed with Stage 4 stomach cancer. Chemotherapy shrank the tumor. That opened the door to a more aggressive option: surgery combined with intensive chemotherapy at MD Anderson Cancer Center in Houston. In 2023, the family traveled to Texas for it.

Then came the call. According to NBC, the MD Anderson surgeon argued repeatedly that the procedure could save Tracy Pike’s life. His wife, Angela, said the surgeon “thought it would be an easy appeal.” Blue Cross kept saying no. The denial was never reversed.

The insurer’s position that the treatment was unproven is harder to square with the medical literature than it sounds. NBC reported that guidelines from the National Comprehensive Cancer Network, a nonprofit alliance of leading cancer centers, recommend the procedure Pike sought for “a select group of patients after multidisciplinary evaluation and discussion as well as appropriate clinical context.” That is a narrow recommendation, not a blanket one. But it is exactly the kind of judgment a multidisciplinary team at a top cancer center exists to make, and MD Anderson made it.

The last straw

For Angela Pike, one detail stood above the rest. She learned that one of the insurer’s physicians who rejected the treatment was not a cancer doctor at all. He was an obstetrician-gynecologist. She told NBC that was the last straw.

Tracy Pike died in January 2024, leaving his wife of 22 years and their three children. Angela has been left with the question NBC put in its headline. “I cannot help but go back to that month in Texas — what would have happened if he had had that surgery? Would he have lived?” she said. “This is just the ripple effect when an insurance company says you can’t get a lifesaving treatment.”

Nobody can answer her question with certainty. Stage 4 stomach cancer is brutal, and no surgeon can promise a cure. That uncertainty is precisely the point. The decision about whether a desperately ill man should get his best remaining chance belonged with the specialists treating him, not with a reviewer from an unrelated field.

Blue Cross and Blue Shield of Illinois declined to discuss Pike’s case with NBC, citing company protocol. A spokesman said the insurer is “committed to increasing access to safe, appropriate, and effective health care,” and aims to provide care based on the best available information and in accordance with a member’s benefit plan.

Not one bad call

Pike’s case is not an outlier. NBC cited Commonwealth Fund survey data finding that 17 percent of Americans said an insurer had denied care their doctor recommended, and more than half of them did not challenge the denial.

Cancer doctors have been sounding the alarm for years. In a 2022 survey of 300 of its U.S. members by the American Society of Clinical Oncology, 96 percent reported delays in treatment caused by prior authorization, the process by which insurers must sign off before care is delivered. Eighty percent reported patients whose disease progressed while they waited. Thirty-six percent reported patients who died. Respondents said insurers took about five business days, on average, to answer a request.

NBC also reported that the share of nonspecialty branded cancer drugs requiring prior approval climbed from 16 percent in 2010 to 78 percent in 2020. American Medical Association President Dr. Bruce Scott put it simply: “Nowhere are the stakes higher than in cancer care.”

Washington finally noticed

In June 2025, HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz announced that major insurers, including UnitedHealthcare and Aetna, had pledged to reduce the number of services requiring prior authorization, standardize electronic requests, expand real-time responses and ensure medical reviews for denied requests. “We want less red tape,” Oz said. “And if we do that, we can cut tens of billions of dollars of administrative waste.”

That pledge is a start, and the industry deserves to be held to it. But a voluntary promise does not answer the question Angela Pike is still asking. The fix that matters is simple to state: when a cancer specialist says a treatment could save a patient’s life, the person overruling that specialist should at minimum be qualified to treat that cancer, and should have to put a name and a reason on the record.

A cancer surgeon said the operation could save Tracy Pike’s life, and the doctor who helped say no was an obstetrician-gynecologist.

Editor’s note: This article covers an NBC News investigation published in December 2024 into a January 2024 death, which drew renewed attention in October 2026.

More from The Rothman Report

Paralympian Veteran Waited 5 Years for a Wheelchair Lift. She Says Canada Offered Her Assisted Death.Glenview Teen Shot Dead at Home: Sheriff Says Evidence Is There, Cook County Still Won’t ChargeRhode Island Ruled Him Incompetent for 23 Years and Let Him Walk. Now a Toddler Was Stabbed in Her Stroller.